High frequency of lipoprotein risk levels for cardiovascular disease in Takayasu arteritis

被引:26
作者
de Carvalho, Jozelio Freire
Bonfa, Eloisa
Bezerra, Mailze C.
Rodrigues Pereira, Rosa Maria [1 ]
机构
[1] Univ Sao Paulo, Fac Med, Disciplina Reumatol, BR-01246903 Sao Paulo, Brazil
关键词
C-reactive protein; Dyslipidemia; Inflammatory markers; Lipid profile; Takayasu arteritis; Vasculitis; ATHEROSCLEROSIS; CHOLESTEROL; DENSITY; PROFILES; LESIONS;
D O I
10.1007/s10067-009-1153-8
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The objective of this study is to characterize the lipoprotein risk levels in Takayasu arteritis (TA) patients and its possible association with disease activity and glucocorticoid use. Twenty-five female TA patients were consecutively included and compared with 30 age-, gender-, and body mass index-matched healthy controls. Demographic features and the lipid profile were determined and cardiovascular risk levels were evaluated according to NCEP/ATPIII. Total cholesterol (TC), LDL-c, HDL-c, and triglycerides were determined after a 12-h overnight fast. Exclusion criteria were conditions that interfere in the lipid profile. The disease duration was 6.6 +/- 7.4 years; 30% had clinical activity and 80% had laboratory activity. Regarding NCEP/ATPIII risk levels, TA patients presented higher frequency of lipid risk compared to controls: high TC (48% vs. 20%, p = 0.04), low HDL-c (20% vs. 0%, p = 0.015), and high triglycerides (36% vs. 10%, p = 0.026). No difference was observed related to LDL-c risk levels between both groups (40% vs. 20%, p = 0.14). Remarkably, 60% of the patients had at least one lipid risk factor for cardiovascular disease. No difference in the lipids was observed between patients with and without clinical activity; however, those with laboratory activity showed lower levels of HDL-c (1.37 +/- 0.42 vs. 2.00 +/- 0.63 mmol/L, p = 0.012) than patients without this activity. A negative correlation was found between HDL-c and CRP levels (r = -0.42, p = 0.04). Lipids were similar in patients under glucocorticoid compared to those without this therapy. This is the first study to identify that TA, an inflammatory disease, has a proatherogenic lipid profile which is associated to laboratory disease activity.
引用
收藏
页码:801 / 805
页数:5
相关论文
共 37 条
[1]  
AlRayyes O, 1997, HEPATOLOGY, V26, P967, DOI 10.1053/jhep.1997.v26.pm0009328321
[2]  
AREND WP, 1990, ARTHRITIS RHEUM, V33, P1129
[3]   LIPID AND APOLIPOPROTEIN PROFILES OF UREMIC DYSLIPOPROTEINEMIA - RELATION TO RENAL-FUNCTION AND DIALYSIS [J].
ATTMAN, PO ;
ALAUPOVIC, P .
NEPHRON, 1991, 57 (04) :401-410
[4]   Low bone density and low serum levels of soluble RANK ligand are associated with severe arterial calcification in patients with Takayasu arteritis [J].
Bezerra, MC ;
Calomeni, GD ;
Caparbo, VF ;
Gebrim, ES ;
Rocha, MS ;
Pereira, RMR .
RHEUMATOLOGY, 2005, 44 (12) :1503-1506
[5]   Dyslipoproteinemias in systemic lupus erythematosus: influence of disease, activity, and anticardiolipin antibodies [J].
Borba, EF ;
Bonfa, E .
LUPUS, 1997, 6 (06) :533-539
[6]   LIPOPROTEIN DISORDERS IN DIABETES-MELLITUS [J].
BROWN, WV .
MEDICAL CLINICS OF NORTH AMERICA, 1994, 78 (01) :143-161
[7]   Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) [J].
Cleeman, JI ;
Grundy, SM ;
Becker, D ;
Clark, LT ;
Cooper, RS ;
Denke, MA ;
Howard, WJ ;
Hunninghake, DB ;
Illingworth, DR ;
Luepker, RV ;
McBride, P ;
McKenney, JM ;
Pasternak, RC ;
Stone, NJ ;
Van Horn, L ;
Brewer, HB ;
Ernst, ND ;
Gordon, D ;
Levy, D ;
Rifkind, B ;
Rossouw, JE ;
Savage, P ;
Haffner, SM ;
Orloff, DG ;
Proschan, MA ;
Schwartz, JS ;
Sempos, CT ;
Shero, ST ;
Murray, EZ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (19) :2486-2497
[8]   Anti-lipoprotein lipase antibodies -: A new player in the complex atherosclerotic process in systemic lupus erythematosus? [J].
de Carvalho, JF ;
Borba, EF ;
Viana, VST ;
Bueno, C ;
Leon, EP ;
Bonfá, E .
ARTHRITIS AND RHEUMATISM, 2004, 50 (11) :3610-3615
[9]   Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels - Results of AFCAPS/TexCAPS [J].
Downs, JR ;
Clearfield, M ;
Weis, S ;
Whitney, E ;
Shapiro, DR ;
Beere, PA ;
Langendorfer, A ;
Stein, EA ;
Kruyer, W ;
Gotto, AM .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 279 (20) :1615-1622
[10]  
Filer A, 2001, J RHEUMATOL, V28, P2752